NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system including neurological and psychiatric disorders, today announced that additional data from a 12-month open-label trial of its transdermal migraine patch (also referred to as Zelrix and NP101) and two other Zelrix trials will be presented at the 53rd Annual Scientific Meeting of the American Headache Society (AHS) this week in Washington, DC... 
More...
More...